Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro

Nanoscale Research Letters

Volumn 9, Issue 1, 2014, Pages

  Imai, Shunji ^a   Yoshioka, Yasuo ^a   Morishita, Yuki ^a   Yoshida, Tokuyuki ^a   Uji, Miyuki ^a   Nagano, Kazuya ^b   Mukai, Yohei ^b   Kamada, Haruhiko ^a,b   Tsunoda, Shin ichi ^a,b   Higashisaka, Kazuma ^a   Tsutsumi, Yasuo ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

CYP3A4; Human liver microsomes; Nanomaterials; Silica nanoparticles; Size; Surface modification

Indexed keywords

ADDITIVES; ENZYMES; METABOLISM; NANOPARTICLES; NANOSTRUCTURED MATERIALS; SILICA; SURFACE TREATMENT;

CARBOXYL MODIFICATIONS; CYP3A4; CYTOCHROME P450-3A4; HUMAN LIVER MICROSOMES; INHIBITORY ACTIVITY; SIZE; SURFACE CHARACTERISTICS; UNDESIRABLE EFFECTS;

SILICA NANOPARTICLES;

EID: 84928694024     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-9-651     Document Type: Article

References (30)

1. Cormode DP, Jarzyna PA, Mulder WJ, Fayad ZA: Modified natural nanoparticles as contrast agents for medical imaging.Adv Drug Deliv Rev 2010, 62:329–338.
2. Kaur IP, Agrawal R: Nanotechnology: a new paradigm in cosmeceuticals.Recent Pat Drug Deliv Formul 2007, 1:171–182.
3. Fadeel B, Garcia-Bennett AE: Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.Adv Drug Deliv Rev 2010, 62:362–374.
4. Wang H, Du LJ, Song ZM, Chen XX: Progress in the characterization and safety evaluation of engineered inorganic nanomaterials in food.Nanomedicine 2013, 8:2007–2025.
5. Mody KT, Popat A, Mahony D, Cavallaro AS, Yu C, Mitter N: Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery.Nanoscale 2013, 5:5167–5179.
6. Ciriminna R, Sciortino M, Alonzo G, Schrijver A, Pagliaro M: From molecules to systems: sol–gel microencapsulation in silica-based materials.Chem Rev 2011, 111:765–789.
7. Peters R, Kramer E, Oomen AG, Rivera ZE, Oegema G, Tromp PC, Fokkink R, Rietveld A, Marvin HJ, Weigel S, Peijnenburg AA, Bouwmeester H: Presence of nano-sized silica during in vitro digestion of foods containing silica as a food additive.ACS Nano 2012, 6:2441–2451.
8. Dekkers S, Krystek P, Peters RJ, Lankveld DP, Bokkers BG, van Hoeven-Arentzen PH, Bouwmeester H, Oomen AG: Presence and risks of nanosilica in food products.Nanotoxicology 2011, 5:393–405.
9. Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Matsuo K, Arimori A, Isobe M, Tochigi S, Kondoh S, Hirai T, Akase T, Yamashita T, Yamashita K, Yoshida T, Nagano K, Abe Y, Yoshioka Y, Kamada H, Imazawa T, Itoh N, Nakagawa S, Mayumi T, Tsunoda S, Tsutsumi Y: Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application.Biomaterials 2011, 32:2713–2724.
10. Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Arimori A, Isobe M, Tochigi S, Kondoh S, Hirai T, Akase T, Yamashita T, Yamashita K, Yoshida T, Nagano K, Abe Y, Yoshioka Y, Kamada H, Imazawa T, Itoh N, Kondoh M, Yagi K, Mayumi T, Tsunoda S, Tsutsumi Y: Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure.Nanotechnology 2012, 23:045101.
11. Guengerich FP: Cytochrome P-450 3A4: regulation and role in drug metabolism.Annu Rev Pharmacol Toxicol 1999, 39:1–17.
12. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG: Drugs as CYP3A probes, inducers, and inhibitors.Drug Metab Rev 2007, 39:699–721.
13. Scheen AJ: Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.Clin Pharmacokinet 2007, 46:93–108.
14. Srinivas NR: Is there a place for drug combination strategies using clinical pharmacology attributes?–review of current trends in research.Curr Clin Pharmacol 2009, 4:220–228.
15. Rahimi R, Abdollahi M: An update on the ability of St. John’s wort to affect the metabolism of other drugs.Expert Opin Drug Metab Toxicol 2012, 8:691–708.
16. Frohlich E, Kueznik T, Samberger C, Roblegg E, Wrighton C, Pieber TR: Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes.Toxicol Appl Pharmacol 2010, 242:326–332.
17. Lamb JG, Hathaway LB, Munger MA, Raucy JL, Franklin MR: Nanosilver particle effects on drug metabolism in vitro.Drug Metab Dispos 2010, 38:2246–2251.
18. Fu C, Liu T, Li L, Liu H, Chen D, Tang F: The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes.Biomaterials 2013, 34:2565–2575.
19. Yoshida T, Yoshioka Y, Tochigi S, Hirai T, Uji M, Ichihashi K, Nagano K, Abe Y, Kamada H, Tsunoda S, Nabeshi H, Higashisaka K, Yoshikawa T, Tsutsumi Y: Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice.Part Fibre Toxicol 2013, 10:41.
20. Li X, Kondoh M, Watari A, Hasezaki T, Isoda K, Tsutsumi Y, Yagi K: Effect of 70-nm silica particles on the toxicity of acetaminophen, tetracycline, trazodone, and 5-aminosalicylic acid in mice.Pharmazie 2011, 66:282–286.
21. Nishimori H, Kondoh M, Isoda K, Tsunoda S, Tsutsumi Y, Yagi K: Influence of 70 nm silica particles in mice with cisplatin or paraquat-induced toxicity.Pharmazie 2009, 64:395–397.
22. Li AP: Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.Drug Metab Dispos 2009, 37:1598–1603.
23. Yamashita K, Yoshioka Y, Higashisaka K, Mimura K, Morishita Y, Nozaki M, Yoshida T, Ogura T, Nabeshi H, Nagano K, Abe Y, Kamada H, Monobe Y, Imazawa T, Aoshima H, Shishido K, Kawai Y, Mayumi T, Tsunoda S, Itoh N, Yoshikawa T, Yanagihara I, Saito S, Tsutsumi Y: Silica and titanium dioxide nanoparticles cause pregnancy complications in mice.Nat Nanotechnol 2011, 6:321–328.
24. Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Tochigi S, Kondoh S, Hirai T, Akase T, Nagano K, Abe Y, Yoshioka Y, Kamada H, Itoh N, Tsunoda S, Tsutsumi Y: Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes.Part Fibre Toxicol 2011, 8:1.
25. Nabeshi H, Yoshikawa T, Arimori A, Yoshida T, Tochigi S, Hirai T, Akase T, Nagano K, Abe Y, Kamada H, Tsunoda S, Itoh N, Yoshioka Y, Tsutsumi Y: Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages.Nanoscale Res Lett 2011, 6:93.
26. Higashisaka K, Yoshioka Y, Yamashita K, Morishita Y, Fujimura M, Nabeshi H, Nagano K, Abe Y, Kamada H, Tsunoda S, Yoshikawa T, Itoh N, Tsutsumi Y: Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials.Biomaterials 2011, 32:3–9.
27. Deng ZJ, Liang M, Toth I, Monteiro MJ, Minchin RF: Molecular interaction of poly(acrylic acid) gold nanoparticles with human fibrinogen.ACS Nano 2012, 6:8962–8969.
28. Bertoli F, Davies GL, Monopoli MP, Moloney M, Gun’ko YK, Salvati A, Dawson KA: Magnetic nanoparticles to recover cellular organelles and study the time resolved nanoparticle-cell interactome throughout uptake.Small 2014, 10:3307–3315.
29. Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, Mou CY, Chen YC, Huang DM: The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3 T3-L1 cells and human mesenchymal stem cells.Biomaterials 2007, 28:2959–2966.
30. Ekkapongpisit M, Giovia A, Follo C, Caputo G, Isidoro C: Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups.Int J Nanomedicine 2012, 7:4147–4158.